ArticleNeurogastroenterology and motility2026
Perlecan, CollagenXVIII, and Agrin Expression in Normo-, Hypo-, and Aganglionic Segments in Hirschsprung's Disease.
Article in Neurogastroenterology and motility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Perlecan, CollagenXVIII, and Agrin Expression in Normo-, Hypo-, and Aganglionic Segments in Hirschsprung's Disease.Neurogastroenterology and motility · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSecretory heparan sulphate proteoglycans (HSPGs) interact with various morphogens, growth factors, and signaling molecules contributing to the development of the enteric nervous system (ENS). Thus, HSPGs have come into focus as pathomechanistic players of enteric neuropathies, such as Hirschsprung's disease (HSCR) in animal models. However, a detailed description of HSPG expression in human HSCR patients is missing.
methodsWe characterized the expression pattern of the secretory HSPGs perlecan, COL18A1, and agrin in the human ENS and investigated differences in affected and healthy intestinal segments. Thus, comparative immunostainings were performed on human gut samples from HSCR-patients and on non-HSCR controls as well as tissues from human body donors. KEY
resultsStrikingly, we found that perlecan, COL18A1, and agrin were expressed as periganglionic basement membrane-like structures in the human ENS. Interestingly, the expression pattern in normoganglionic and hypoganglionic HSCR-tissues was comparable to the expression pattern in control tissues, despite the loss of neuronal differentiation markers in hypoganglionic segments. In aganglionic segments, the immunoreactivity of the investigated secretory HSPGs in the intermuscular layer was markedly reduced or not detectable. Yet, they were still readily visible in the Tunica muscularis, around blood vessels, and in the epithelium, with an almost unaltered immunoreactive pattern compared to the ganglionic segment.
conclusionOur study transferred valuable findings on the role of HSPGs in ENS development gained in animal models to human HSCR patients. Beyond their implications for understanding enteric neuropathies, we discuss our findings in the context of how the extracellular matrix might regulate homeostasis and regeneration in the human ENS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.